OncoMatch/Clinical Trials/NCT06384222
Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone
Is NCT06384222 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Abiraterone acetate and Prednisone for high risk prostate carcinoma.
Treatment: Abiraterone acetate · Prednisone · Hyperpolarized [1-13C] pyruvate (HP 13C) — This study will evaluate the use of hyperpolarized 13C MRI (HP 13C MRI) and the HP-derived 13C pyruvate-to-lactate conversion rate constant (kPL) as an early response biomarker in men with treatment-naïve, high-risk, localized or locally advanced prostate cancer receiving neoadjuvant therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Endocrine / hormonal
Other
Cancer type
Prostate Cancer
Disease stage
Required: Stage HIGH-RISK, CN1, T3 OR HIGHER
Excluded: Stage DISTANT METASTATIC DISEASE
Grade: Gleason grade group >=4 (Gleason)
High-risk disease defined as meeting 1 or more of the 3 following criteria: 1. Gleason grade group >=4; or 2. Pelvic node involvement by conventional imaging or PSMA PET imaging (cN1); or 3. Tumor stage T3 or higher
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: prostate cancer therapy
Exception: Prior 5-alpha reductase inhibitors (e.g. finasteride, dutasteride) allowed if discontinued at least 3 weeks prior to first dose.
Has received prior prostate cancer therapy. Prior 5-alpha reductase inhibitors (e.g. finasteride, dutasteride) allowed if discontinued at least 3 weeks prior to first dose.
Lab requirements
Blood counts
Absolute neutrophil count (ANC) >=1,500/mcL. Platelets >=100,000/mcL, independent of transfusions/growth factors within 3 months of treatment start.
Kidney function
Estimated creatinine clearance >=40 mL/min (by the Cockcroft Gault equation).
Liver function
Total bilirubin within normal institutional limits, unless elevated due to Gilbert's syndrome and direct bilirubin is within normal limits. AST/SGOT <=3 X institutional upper limit of normal. ALT/SGPT <=3 X institutional upper limit of normal.
Demonstrates adequate organ function as defined below: 1. Absolute neutrophil count (ANC) >=1,500/mcL. 2. Platelets >=100,000/mcL, independent of transfusions/growth factors within 3 months of treatment start. 3. Total bilirubin within normal institutional limits, unless elevated due to Gilbert's syndrome and direct bilirubin is within normal limits. 4. AST/SGOT <=3 X institutional upper limit of normal. 5. ALT/SGPT <=3 X institutional upper limit of normal. 6. Estimated creatinine clearance >=40 mL/min (by the Cockcroft Gault equation).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, San Francisco · San Francisco, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06384222 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage HIGH-RISK or CN1 or T3 OR HIGHER is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages